Compounds > 1-anilino-8-naphthalenesulfonate

Page last updated: 2024-10-21

1-anilino-8-naphthalenesulfonate and Chronic Hepatitis B

1-anilino-8-naphthalenesulfonate has been researched along with Chronic Hepatitis B in 17 studies

1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.

Research Excerpts

Excerpt	Relevance	Reference
" Overall, 32 (26%) patients reported an adverse event."	6.90	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. ( Buti, M; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Gane, E; Janssen, HLA; Jump, B; Kaita, K; Kitrinos, K; Manns, M; Marcellin, P; Op den Brouw, M; Wong, DK, 2019)
" Overall, 32 (26%) patients reported an adverse event."	2.90	Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. ( Buti, M; Crans, G; Flaherty, J; Flisiak, R; Gaggar, A; Gane, E; Janssen, HLA; Jump, B; Kaita, K; Kitrinos, K; Manns, M; Marcellin, P; Op den Brouw, M; Wong, DK, 2019)
"Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries."	2.55	New trends on obesity and NAFLD in Asia. ( Fan, JG; Kim, SU; Wong, VW, 2017)
"The prevalence of steatohepatitis increased with PNPLA3 CC (14%), CG (20%) and GG (43%) (P < 0."	1.42	The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. ( Boonstra, A; Brouwer, WP; de Knegt, RJ; de Man, RA; Hansen, BE; Janssen, HL; Pas, SD; ten Kate, FJ; van der Meer, AJ, 2015)
"In patients with both CHB and NAFLD, these genotypes of PNPLA3 polymorphisms were associated with increased susceptibility to nonalcoholic steatohepatitis (NASH) (NAFLD activity score ≥ 3; P = 0."	1.42	Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. ( Chen, GY; Chen, YM; Fan, JG; Liu, WB; Lu, JF; Mi, YQ; Pan, Q; Shen, F; Sun, WL; Wang, YQ; Zhang, RN; Zhang, SY; Zheng, RD; Zhu, CY, 2015)
"Patients with liver cirrhosis had serum levels of amylase and lipase significantly higher than both the healthy subjects and the patients with CAH, while no significant differences were found in serum levels of these enzymes in patients with CAH as compared to the healthy subjects."	1.30	Serum pancreatic enzyme concentrations in chronic viral liver diseases. ( Andreone, P; Barakat, B; Bernardi, M; Billi, P; Cursaro, C; Fiocchi, M; Gramenzi, A; Miglio, F; Morselli-Labate, AM; Pezzilli, R; Sama, C, 1999)

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (5.88)	18.2507
2000's	2 (11.76)	29.6817
2010's	13 (76.47)	24.3611
2020's	1 (5.88)	2.80

Authors

Authors	Studies
Wang, P	1
Wu, C	1
Li, Y	1
Gong, Y	1
Shen, N	1
Gao, X	1
Liu, W	1
Yang, L	1
Zhang, X	1
Ma, N	1
Wang, L	1
Yan, L	1
Tang, L	1
Yang, H	1
Liu, D	1
Fan, JG	2
Kim, SU	1
Wong, VW	1
Ghalamkari, S	1
Sharafi, H	1
Alavian, SM	1
Raksayot, M	1
Chuaypen, N	1
Khlaiphuengsin, A	1
Pinjaroen, N	1
Treeprasertsuk, S	1
Poovorawan, Y	1
Tanaka, Y	1
Tangkijvanich, P	1
Wang, LQ	1
Guo, WH	1
Guo, ZW	1
Qin, P	1
Zhang, R	1
Zhu, XM	1
Liu, DW	1
Buti, M	1
Wong, DK	1
Gane, E	1
Flisiak, R	1
Manns, M	1
Kaita, K	1
Janssen, HLA	1
Op den Brouw, M	1
Jump, B	1
Kitrinos, K	1
Crans, G	1
Flaherty, J	1
Gaggar, A	1
Marcellin, P	1
Viganò, M	1
Valenti, L	2
Lampertico, P	1
Facchetti, F	1
Motta, BM	1
D'Ambrosio, R	1
Romagnoli, S	1
Dongiovanni, P	2
Donati, B	2
Fargion, S	1
Colombo, M	1
Fares, R	1
Lombardi, R	1
Mancina, RM	1
Romeo, S	1
Jiang, M	1
Xin, Y	1
Wang, W	1
Lin, Z	1
Zhang, D	1
Li, C	1
Jiang, X	1
Xuan, S	1
Brouwer, WP	1
van der Meer, AJ	1
Boonstra, A	1
Pas, SD	1
de Knegt, RJ	1
de Man, RA	1
Hansen, BE	1
ten Kate, FJ	1
Janssen, HL	1
Zampino, R	1
Coppola, N	1
Cirillo, G	1
Boemio, A	1
Grandone, A	1
Stanzione, M	1
Capoluongo, N	1
Marrone, A	1
Macera, M	1
Sagnelli, E	1
Adinolfi, LE	1
del Giudice, EM	1
Pan, Q	1
Zhang, RN	1
Wang, YQ	1
Zheng, RD	1
Mi, YQ	1
Liu, WB	1
Shen, F	1
Chen, GY	1
Lu, JF	1
Zhu, CY	1
Zhang, SY	1
Chen, YM	1
Sun, WL	1
Takeuchi, Y	1
Ikeda, F	1
Moritou, Y	1
Hagihara, H	1
Yasunaka, T	1
Kuwaki, K	1
Miyake, Y	1
Ohnishi, H	1
Nakamura, S	1
Shiraha, H	1
Takaki, A	1
Iwasaki, Y	1
Nouso, K	1
Yamamoto, K	1
Katakura, Y	1
Yotsuyanagi, H	1
Hashizume, K	1
Okuse, C	1
Okuse, N	1
Nishikawa, K	1
Suzuki, M	1
Iino, S	1
Itoh, F	1
Chen, CL	1
Yang, HI	1
Yang, WS	1
Liu, CJ	1
Chen, PJ	1
You, SL	1
Wang, LY	1
Sun, CA	1
Lu, SN	1
Chen, DS	1
Chen, CJ	1
Pezzilli, R	1
Andreone, P	1
Morselli-Labate, AM	1
Sama, C	1
Billi, P	1
Cursaro, C	1
Barakat, B	1
Gramenzi, A	1
Fiocchi, M	1
Miglio, F	1
Bernardi, M	1

Clinical Trials (5)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Non Invasive Evaluation of Liver Fibrosis and Steatosis in Type 2 Diabetic Patient in Assiut University Hospitals[NCT05605717]		60 participants (Anticipated)	Observational	2022-11-01	Not yet recruiting
Clinical Study on the Value of Quantitative MRI Imaging in Diffuse Liver Diseases[NCT04626492]		150 participants (Anticipated)	Observational [Patient Registry]	2020-08-01	Recruiting
Effect of Intermittent Calorie Restriction on Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Abnormal Glucose Metabolism[NCT04283942]		60 participants (Actual)	Interventional	2020-07-30	Completed
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B[NCT00117676]	Phase 3	382 participants (Actual)	Interventional	2005-02-28	Completed
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B[NCT00116805]	Phase 3	266 participants (Actual)	Interventional	2005-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With ALT Normalization at Week 48

ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 48

Intervention	percentage of participants (Number)
TDF-TDF	76.3
ADV-TDF	77.1

Percentage of Participants With ALT Normalization at Weeks 96

ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Week 96

Intervention	percentage of participants (Number)
TDF-TDF	72.4
ADV-TDF	68.5

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00117676)
Timeframe: Week 48

Intervention	percentage of participants (Number)
TDF-TDF	93.2
ADV-TDF	63.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96

(NCT00117676)
Timeframe: Week 96

Intervention	percentage of participants (Number)
TDF-TDF	90.6
ADV-TDF	89.3

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	units per liter (Mean)
	Week 48	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-124.4	-138.5	-140.0	-140.3	-139.5	-134.7	-143.1	-132.6	-131.9	-129.2
TDF-TDF	-95.0	-93.7	-99.1	-99.6	-97.7	-98.9	-98.9	-96.1	-97.0	-94.9

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	log10 copies/mL (Mean)
	Week 48	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-4.07	-4.74	-4.77	-4.75	-4.77	-4.81	-4.81	-4.79	-4.69	-4.75
TDF-TDF	-4.57	-4.54	-4.61	-4.56	-4.59	-4.61	-4.61	-4.56	-4.60	-4.57

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). (NCT00117676)
Timeframe: Baseline; Week 240

Intervention	units on a scale (Mean)
	Knodell Score	Ishak Score
ADV-TDF	-4.9	-4.2
TDF-TDF	-4.6	-4.0

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

Intervention	units on a scale (Mean)
	Knodell Necroinflammatory Score	Ishak Necroinflammatory Score
ADV-TDF	-3.4	-2.6
TDF-TDF	-3.5	-2.6

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	units per liter (Mean)
	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-0.6	-0.3	-3.6	-3.9	-4.1	-2.0	-3.9	-8.9	-5.9
TDF-TDF	2.4	-0.6	0.7	-2.5	-3.9	-2.6	-2.9	-4.6	-2.8

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00117676)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	log10 copies/mL (Mean)
	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-0.60	-0.63	-0.61	-0.61	-0.64	-0.65	-0.66	-0.67	-0.72
TDF-TDF	0.02	-0.03	0.01	-0.04	-0.04	-0.05	-0.02	-0.04	-0.05

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 97 to 144

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	0	0	0	0	0
TDF-TDF	4	0	1	2	1
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 145 to 192

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	0	0	0	0	0
TDF-TDF	3	0	1	1	1
TDF-TDF With Addition of FTC	1	0	0	1	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 193 to 240

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	2	0	0	0	2
TDF-TDF	1	1	0	0	0
TDF-TDF With Addition of FTC	2	0	2	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 241 to 288

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	1	0	1	0	0
TDF-TDF	3	0	2	1	0
TDF-TDF With Addition of FTC	1	0	1	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 289 to 336

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	1	0	0	0	1
TDF-TDF	0	0	0	0	0
TDF-TDF With Addition of FTC	1	0	0	1	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 337 to 384

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	0	0	0	0	0
TDF-TDF	1	0	0	0	1
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 385 to 432

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	1	0	1	0	0
TDF-TDF	2	0	0	2	0
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00117676)
Timeframe: Baseline; Week 48

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	42	7	14	20	1
TDF-TDF	8	0	3	4	1

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 433 to 480

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to genotype
ADV-TDF	0	0	0	0	0
TDF-TDF	0	0	0	0	0
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition. (NCT00117676)
Timeframe: Baseline; Weeks 49 to 96

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites within HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	0	0	0	0	0
TDF-TDF	6	0	2	4	0
TDF-TDF With Addition of FTC	1	0	1	0	0

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

Intervention	percentage of participants (Number)
	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384
ADV-TDF	70.0	76.4	75.7	72.9	65.4	69.2
TDF-TDF	74.3	68.2	70.3	69.9	65.9	65.3

Percentage of Participants With ALT Normalization at Weeks 432 and 480

Intervention	percentage of participants (Number)
	Week 432	Week 480
ADV-TDF	87.2	88.9
TDF-TDF	86.5	80.0

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96. (NCT00117676)
Timeframe: Baseline; Week 96

Intervention	percentage of participants (Number)
	HBsAg Loss	Anti-HBs Seroconversion
ADV-TDF	0	0
TDF-TDF	0	0

Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00117676)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	percentage of participants (Number)
	HBsAg Loss - Week 144	Anti-HBs Seroconversion - Week 144	HBsAg Loss - Week 192	Anti-HBs Seroconversion - Week 192	HBsAg Loss - Week 240	Anti-HBs Seroconversion - Week 240	HBsAg Loss - Week 288	Anti-HBs Seroconversion - Week 288	HBsAg Loss - Week 336	Anti-HBs Seroconversion - Week 336	HBsAg Loss - Week 384	Anti-HBs Seroconversion - Week 384	HBsAg Loss - Week 432	Anti-HBs Seroconversion - Week 432	HBsAg Loss - Week 480	Anti-HBs Seroconversion - Week 480
ADV-TDF	0	0	0	0	0.8	0	0.8	0.8	0.8	0.8	0.8	0.8	1.6	0.8	2.4	0.8
TDF-TDF	0	0	0	0	0	0	0	0	0	0	0.8	0.4	1.2	0.4	1.2	0.8

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

"Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.~A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40." (NCT00117676)
Timeframe: Baseline; Week 48

Intervention	percentage of participants (Number)
	Yes	No
ADV-TDF	48.8	51.2
TDF-TDF	70.8	29.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00117676)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

Intervention	percentage of participants (Number)
	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384
ADV-TDF	88.4	86.8	83.9	82.9	78.0	76.3
TDF-TDF	86.7	84.0	82.8	80.5	77.0	74.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00117676)
Timeframe: Weeks 432 and 480

Intervention	percentage of participants (Number)
	Week 432	Week 480
ADV-TDF	97.7	100.0
TDF-TDF	97.6	100.0

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. (NCT00117676)
Timeframe: Baseline; Week 48

Intervention	percentage of participants (Number)
	HBsAg Loss	Seroconversion to anti-HBs
ADV-TDF	0	0
TDF-TDF	0	0

Percentage of Participants With Histological Response at Week 240

Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. (NCT00117676)
Timeframe: Baseline; Week 240

Intervention	percentage of participants (Number)
	Yes	No
ADV-TDF	85.1	14.9
TDF-TDF	87.3	12.7

Percentage of Participants With Histological Response at Week 48

Intervention	percentage of participants (Number)
	Yes	No
ADV-TDF	68.8	31.2
TDF-TDF	72.4	27.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. (NCT00117676)
Timeframe: Baseline; Week 240

Intervention	percentage of participants (Number)
	Improvement - Necroinflammation	No Change - Necroinflammation	Worsening - Necroinflammation	Improvement - Fibrosis	No Change - Fibrosis	Worsening - Fibrosis
ADV-TDF	94.6	1.4	4.1	59.5	33.8	6.8
TDF-TDF	96.7	2.7	0.7	62.0	34.0	4.0

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Intervention	percentage of participants (Number)
	Improvement - Necroinflammation	No Change - Necroinflammation	Worsening - Necroinflammation	Missing Data - Necroinflammation	Improvement - Fibrosis	No Change - Fibrosis	Worsening - Fibrosis	Missing Data - Fibrosis
ADV-TDF	81.6	8.0	0.8	9.6	25.6	54.4	10.4	9.6
TDF-TDF	82.0	6.8	4.8	6.4	22.0	63.2	8.4	6.4

Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48

Intervention	percentage of participants (Number)
TDF-TDF	68.0
ADV-TDF	54.4

Percentage of Participants With ALT Normalization at Week 96

Intervention	percentage of participants (Number)
TDF-TDF	65.2
ADV-TDF	74.4

Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48

Intervention	percentage of participants (Number)
TDF-TDF	66.5
ADV 10 mg	12.2

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48

(NCT00116805)
Timeframe: Week 48

Intervention	percentage of participants (Number)
TDF-TDF	76.1
ADV-TDF	13.3

Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96

(NCT00116805)
Timeframe: Week 96

Intervention	percentage of participants (Number)
TDF-TDF	77.6
ADV-TDF	77.9

Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	U/L (Mean)
	Week 48	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-106.1	-120.4	-126.2	-139.6	-134.8	-130.9	-132.3	-133.7	-162.1	-157.5
TDF-TDF	-107.2	-107.8	-100.7	-101.4	-95.9	-102.3	-101.9	-108.1	-105.0	-92.3

Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	log10 IU/mL (Mean)
	Week 48	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-3.93	-6.38	-6.31	-6.49	-6.45	-6.49	-6.46	-6.28	-6.45	-6.37
TDF-TDF	-6.17	-6.26	-6.32	-6.30	-6.22	-6.27	-6.35	-6.38	-6.13	-6.18

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240

Intervention	units on a scale (Mean)
	Knodell Necroinflammatory Score	Ishak Necroinflammatory Score
ADV-TDF	-5.1	-4.5
TDF-TDF	-4.8	-4.1

Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48

Intervention	units on a scale (Mean)
	Knodell Necroinflammatory Score	Ishak Necroinflammatory Score
ADV-TDF	-3.2	-2.6
TDF-TDF	-3.6	-2.7

Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	U/L (Mean)
	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-6.9	-0.7	-7.8	-8.1	-10.3	-9.3	-6.9	-11.6	-7.1
TDF-TDF	-2.0	-0.4	-1.3	3.7	-1.6	-1.2	-4.4	-4.3	-5.5

Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

(NCT00116805)
Timeframe: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	log10 IU/mL (Mean)
	Week 96	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384	Week 432	Week 480
ADV-TDF	-2.43	-2.27	-2.41	-2.49	-2.62	-2.59	-2.34	-2.32	-2.16
TDF-TDF	-0.10	-0.19	-0.20	-0.14	-0.18	-0.25	-0.29	-0.13	-0.24

Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	5	2	3	0	0
ADV-TDF With Addition of FTC	5	0	0	3	1
TDF-TDF	2	1	0	1	0
TDF-TDF With Addition of FTC	7	2	3	2	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	1	0	1	0	0
ADV-TDF With Addition of FTC	1	0	1	0	0
TDF-TDF	2	0	1	0	1
TDF-TDF With Addition of FTC	5	0	0	1	3

Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	0	0	0	0	0
ADV-TDF With Addition of FTC	1	1	0	0	0
TDF-TDF	3	0	2	1	0
TDF-TDF With Addition of FTC	3	0	0	2	1

Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	0	0	0	0	0
ADV-TDF With Addition of FTC	0	0	0	0	0
TDF-TDF	3	0	0	2	1
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	1	0	0	1	0
ADV-TDF With Addition of FTC	0	0	0	0	0
TDF-TDF	1	0	0	0	1
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	2	1	1	0	0
ADV-TDF With Addition of FTC	2	0	1	1	0
TDF-TDF	1	0	0	0	1
TDF-TDF With Addition of FTC	0	0	0	0	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	0	0	0	0	0
ADV-TDF With Addition of FTC	1	0	0	1	0
TDF-TDF	1	0	1	0	0
TDF-TDF With Addition of FTC	3	0	0	3	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)

Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL. (NCT00116805)
Timeframe: Baseline; Week 48

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	75	8	17	43	7
TDF-TDF	31	2	13	7	9

Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	1	0	0	1	0
ADV-TDF With Addition of FTC	0	0	0	0	0
TDF-TDF	0	0	0	0	0
TDF-TDF With Addition of FTC	3	0	1	2	0

Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)

,,,

Intervention	participants (Number)
	Participants evaluated	Changes at conserved sites in HBV polymerase	Changes at polymorphic sites in HBV polymerase	No genotypic changes (wild-type virus)	Unable to be genotyped
ADV-TDF	16	2	1	12	1
ADV-TDF With Addition of FTC	10	3	2	3	2
TDF-TDF	18	2	3	10	3
TDF-TDF With Addition of FTC	13	0	1	5	7

Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384

ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, and 384

Intervention	percentage of participants (Number)
	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384
ADV-TDF	67.8	69.4	65.9	70.1	67.9	67.1
TDF-TDF	60.2	59.6	50.0	51.3	46.2	52.6

Percentage of Participants With ALT Normalization at Weeks 432 and 480

Intervention	percentage of participants (Number)
	Week 432	Week 480
ADV-TDF	78.6	82.8
TDF-TDF	79.6	75.0

Percentage of Participants With HBeAg Loss or Seroconversion to Anti-HBe at Week 96

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. (NCT00116805)
Timeframe: Baseline; Week 96

Intervention	percentage of participants (Number)
	HBeAg Loss	Seroconversion to Anti-HBe
ADV-TDF	25.6	22.0
TDF-TDF	25.9	22.8

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Week 96

Intervention	percentage of participants (Number)
	HBsAg Loss	Anti-HBs Seroconversion
ADV-TDF	5.8	4.7
TDF-TDF	5.3	4.1

Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480

HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. (NCT00116805)
Timeframe: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480

Intervention	percentage of participants (Number)
	HBsAg Loss - Week 144	Anti-HBs Seroconversion - Week 144	HBsAg Loss - Week 192	Anti-HBs Seroconversion - Week 192	HBsAg Loss - Week 240	Anti-HBs Seroconversion - Week 240	HBsAg Loss - Week 288	Anti-HBs Seroconversion - Week 288	HBsAg Loss - Week 336	Anti-HBs Seroconversion - Week 336	HBsAg Loss - Week 384	Anti-HBs Seroconversion - Week 384	HBsAg Loss - Week 432	Anti-HBs Seroconversion - Week 432	HBsAg Loss - Week 480	Anti-HBs Seroconversion - Week 480
ADV-TDF	8.0	6.8	7.9	6.7	8.0	8.0	8.0	8.0	7.9	7.9	9.0	7.9	10.2	8.0	10.1	7.9
TDF-TDF	7.5	5.2	9.4	6.4	9.2	6.3	9.2	6.4	10.3	7.5	11.0	8.1	10.9	7.6	10.9	8.0

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384

(NCT00116805)
Timeframe: Weeks 144, 192, 240, 288, 336, and 384

Intervention	percentage of participants (Number)
	Week 144	Week 192	Week 240	Week 288	Week 336	Week 384
ADV-TDF	70.5	71.6	66.3	64.8	62.1	60.5
TDF-TDF	71.7	67.9	63.4	61.3	59.4	56.1

Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480

(NCT00116805)
Timeframe: Weeks 432 and 480

Intervention	percentage of participants (Number)
	Week 432	Week 480
ADV-TDF	100.0	96.6
TDF-TDF	93.0	98.0

Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss/Seroconversion at Week 48

HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. (NCT00116805)
Timeframe: Baseline; Week 48

Intervention	percentage of participants (Number)
	HBeAg Loss	HBeAg Seroconversion
ADV-TDF	17.5	17.5
TDF-TDF	22.2	20.9

Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48

Intervention	percentage of participants (Number)
	HBsAg Loss	HBsAg Seroconversion
ADV-TDF	0	0
TDF-TDF	3.2	1.3

Percentage of Participants With Histological Response at Week 240

Intervention	percentage of participants (Number)
	Yes	No
ADV-TDF	89.6	10.4
TDF-TDF	88.2	11.8

Percentage of Participants With Histological Response at Week 48

Intervention	percentage of participants (Number)
	Yes	No
ADV-TDF	67.8	32.2
TDF-TDF	74.4	25.6

Ranked Assessment of Necroinflammation and Fibrosis at Week 240

Intervention	percentage of participants (Number)
	Improvement - Necroinflammation	No Change - Necroinflammation	Worsening - Necroinflammation	Improvement - Fibrosis	No Change - Fibrosis	Worsening - Fibrosis
ADV-TDF	97.9	2.1	0	58.3	39.6	2.1
TDF-TDF	96.1	3.9	0	56.6	39.5	3.9

Ranked Assessment of Necroinflammation and Fibrosis at Week 48

Intervention	percentage of participants (Number)
	Improvement - Necroinflammation	No Change - Necroinflammation	Worsening - Necroinflammation	Missing Data - Necroinflammation	Improvement - Fibrosis	No Change - Fibrosis	Worsening - Fibrosis	Missing Data - Fibrosis
ADV-TDF	78.9	3.3	5.6	12.2	20.0	61.1	6.7	12.2
TDF-TDF	81.3	4.5	3.4	10.8	19.9	63.6	5.1	11.4

Reviews

4 reviews available for 1-anilino-8-naphthalenesulfonate and Chronic Hepatitis B

Article	Year
PNPLA3 rs738409 is not associated with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus (HBV) in HBV-related subjects: A case-control study and meta-analysis on Asians. Gene, 2020, Jun-05, Volume: 742 Topics: Adult; Aged; Asian People; Carcinoma, Hepatocellular; Case-Control Studies; Female; Genetic Predispo	2020
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
New trends on obesity and NAFLD in Asia. Journal of hepatology, 2017, Volume: 67, Issue:4 Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide	2017
Association of PNPLA3 rs738409 polymorphism with liver steatosis but not with cirrhosis in patients with HBV infection: Systematic review with meta-analysis. The journal of gene medicine, 2018, Volume: 20, Issue:1 Topics: Fatty Liver; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lipase; Liver Cirrhosis; Me	2018
PNPLA3 I148M polymorphism and progressive liver disease. World journal of gastroenterology, 2013, Nov-07, Volume: 19, Issue:41 Topics: Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Disease Progression; Fatty Liver; Fatty Liver, A	2013

Trials

1 trial available for 1-anilino-8-naphthalenesulfonate and Chronic Hepatitis B

Article	Year
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4 Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatiti	2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4 Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatiti	2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4 Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatiti	2019
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4 Topics: Adult; Alanine Transaminase; DNA, Viral; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatiti	2019

Other Studies

12 other studies available for 1-anilino-8-naphthalenesulfonate and Chronic Hepatitis B

Article	Year
Association between PNPLA3 gene polymorphisms and risk of hepatitis B virus-related hepatocellular carcinoma in Han population in China:a case-control study. Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:10 Topics: Adult; Aged; Asian People; Carcinoma, Hepatocellular; Case-Control Studies; China; Female; Genetic P	2017
Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. Journal of gastroenterology, 2019, Volume: 54, Issue:5 Topics: Acyltransferases; Aged; Alleles; Carcinoma, Hepatocellular; Case-Control Studies; Chondroitin Sulfat	2019
[Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 2018, Dec-10, Volume: 39, Issue:12 Topics: Alcohol Drinking; Carcinoma, Hepatocellular; Case-Control Studies; Epistasis, Genetic; Gene-Environm	2018
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:4 Topics: Adult; Alcoholism; Cohort Studies; Disease Progression; Fatty Liver; Female; Genetic Predisposition	2013
[Association between the PNPLA3 I148M polymorphism and chronic hepatitis B in a Qingdao Han Chinese population]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2014, Volume: 22, Issue:5 Topics: Adult; Aged; Asian People; Case-Control Studies; China; Female; Gene Frequency; Genetic Predispositi	2014
The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2 Topics: Body Weight; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis B, Chronic; Humans; Iron; Lip	2015
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. Digestive diseases and sciences, 2015, Volume: 60, Issue:10 Topics: Abdominal Fat; Adult; Aged; Anthropometry; Body Mass Index; Chi-Square Distribution; Cohort Studies;	2015
Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World journal of gastroenterology, 2015, Jul-28, Volume: 21, Issue:28 Topics: Adult; Asian People; Biomarkers; Biopsy; Case-Control Studies; China; DNA, Viral; Female; Gene Frequ	2015
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. Journal of gastroenterology, 2013, Volume: 48, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Carcinoma, Hepatocellular; Female; Follow-Up Studie	2013
Pancreatic involvement in chronic viral hepatitis. World journal of gastroenterology, 2005, Jun-21, Volume: 11, Issue:23 Topics: Adult; Aged; Amylases; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lipase; Male; Mid	2005
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 2008, Volume: 135, Issue:1 Topics: Adult; Carbolines; Carcinoma, Hepatocellular; Diabetes Mellitus; Female; Follow-Up Studies; Hepatiti	2008
Serum pancreatic enzyme concentrations in chronic viral liver diseases. Digestive diseases and sciences, 1999, Volume: 44, Issue:2 Topics: Adolescent; Adult; Aged; Amylases; Chronic Disease; Female; Hepatitis B, Chronic; Hepatitis C, Chron	1999